Individuals with a history of pancreatitis or severe kidney disease should also avoid this medication
Many individuals hesitate to start injectable treatments due to fear or inconvenience
Although much has improved since the first generation came on the market in 2005, pharmaceutical companies are investing significant resources to address four main obstacles: GLP-1 drugs significantly alter consumer behavior
Early Phase 2 trial data have generated significant clinical interest, but retatrutide has not yet received MHRA or EMA authorisation and remains confined to research settings

The Five Core GLP-1 Patient Personas The Career Burnout Professional (high stress metabolic imbalance) The Busy Parent (time scarcity and emotional exhaustion) The Yo-Yo Dieter (history of failure and skepticism) The Silent Sufferer (body image, shame, and privacy concerns) The Performance Optimizer (results-focused, analytical mindset) Foundational Persona Development Demographics, psychographics, and core motivations Problems patients recognize versus problems they avoid Barriers to telehealth adoption in weight-loss care Technical barriers: Poor internet access and a lack of devices, especially in rural and low-income areas Knowledge gaps: Many older adults who need treatment the most struggle with digital technology Logistical constraints: Rural families find it hard to manage time and scheduling Privacy concerns: Many worry about stigma, even in virtual visits Advanced Persona Modeling for GLP-1 Programs Mapping belief systems and internal narratives Journey mapping: awareness intake first prescription refill Intake: This vital phase brings multiple specialists who manage symptoms and disease
